RVMD — Revolution Medicines Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Price data
- Price
- $199.70
- YTD price return
- +150.72%
- YTD total return
- +150.72%
- Market cap
- 43.2B
- Enterprise value
- 40.2B
- Shares outstanding
- 216.3M
- 52W low
- $57.74
- 52W high
- $224.31
- From 52W high
- -10.97%
- From 52W low
- +245.86%
- 52W range
- 85%$57.74–$224
- Beta
- 1.39
Volume
- Rel volume
- 1.25×
- 30D volume
- 2M
- 30D $ vol
- 387M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- −$432K
- Insider net 3M
- −$78.4M
- Insider net 1Y
- −$140.3M
Form 4 transactions by trade date, as filed; latest on file 2026-10-26.
Fundamentals
- Sales (ttm)
- 197.6M
- Sales/share
- $0.91
- EPS (ttm)
- -$9.14
- FCF (ttm)
- -1.4B
- FCF/share
- -$6.66
- Book value/share
- $11.10
- Net margin
- -946.82%
- ROE
- -77.89%
- ROA
- -43.47%
- Debt / equity
- 0.20×
- Current ratio
- 8.36
Growth (CAGR, ttm) · 10Y
- Sales
- n/a+180.67%+47.11%n/a
- Shares
- +11.89%+25.44%+24.03%n/a
Per-share growth (CAGR, ttm) · 10Y
- Sales/share
- n/a+154.17%+18.60%n/a
- Book value/share
- +34.44%+13.25%+5.09%n/a
- Price
- +241.25%+107.93%+42.95%n/a
- Total return
- +241.25%+107.93%+42.95%n/a
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- -21.8×
- Fwd P/E
- -33.2×
- P/S (ttm)
- 218.6×
- P/B (mrq)
- 18.0×
- EV/Sales (ttm)
- 203.4×
- FCF yield (ttm)
- -3.34%
- Buyback yield (realized, 1y)
- -11.89%
- Shareholder yield (realized, 1y)
- -11.89%
- Buyback yield (cash, ttm)
- -3.82%
- Shareholder yield (cash, ttm)
- -3.82%
Vs own 10Y history
- P/S
- 83rd
- P/B
- 96th
Bar = where today’s multiple sits in RVMD’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-04#
Fundamentals#
Operating income
5Y n/m5Y n/mYoY n/mEPS (diluted)
5Y n/m5Y n/mYoY n/mFree cash flow
5Y n/m5Y n/mYoY n/mTTM: operating cash flow −$1.4B, capex −$9.4M
Q3 2026: operating cash flow −$415.6M, capex −$3.7M
Shares (diluted)
5Y +246.5%5Y +246.5%YoY +13.6%Net income
5Y n/m5Y n/mYoY n/mAbout Revolution Medicines#
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing targeted therapies for RAS-addicted cancers. The company applies proprietary drug discovery capabilities to create small-molecule medicines designed to act on challenging RAS pathway targets, a central driver in many aggressive tumors. Its current pipeline includes RAS(ON) inhibitors and companion inhibitors being studied as monotherapies and in combination regimens to address cancers with specific RAS mutations and related pathway dependencies. Revolution Medicines concentrates on areas of high unmet medical need, including pancreatic, lung, and colorectal cancers, and its work is aimed at improving how these diseases are treated in modern oncology practice. Headquartered in Redwood City, California, and founded in 2014, Revolution Medicines occupies a specialized position in the biotechnology sector through its focus on advanced precision medicine approaches.
Redwood City, CA·883 employees·Biotechnology·revmed.com·As of Oct 28, 2026
Recent filings#
- Nov 4Earnings · Earnings release — EPS −$1.61 vs −$2.34 est.; revenue $197.6M
- Aug 5Earnings · Earnings release — EPS −$2.34 vs −$1.93 est. (−21.2%) 0.3%
ETFs holding RVMD#
20 of the 193 ETFs ChartRow carries live hold RVMD. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| IBB | iShares Biotechnology ETF | 2.8% |
| XBI | SPDR S&P Biotech ETF | 1.2% |
| VBK | Vanguard Small-Cap Growth ETF | 1.1% |
| IWP | iShares Russell Mid-Cap Growth ETF | 1.0% |
| VHT | Vanguard Health Care ETF | 0.5% |
| VB | Vanguard Small-Cap ETF | 0.5% |
| VXF | Vanguard Extended Market ETF | 0.4% |
| IWR | iShares Russell Midcap ETF | 0.3% |
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +24.07% | +0.61% |
| JNJ | Johnson & Johnson | +7.92% | +3.81% |
| ABBV | AbbVie Inc. | +12.18% | +3.09% |
| MRK | Merck & Co. Inc. | +4.20% | +3.93% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +10.08% | +1.22% |
| NVS | Novartis AG | +17.01% | +3.59% |
| TMO | Thermo Fisher Scientific Inc. | +7.84% | +1.12% |
| AMGN | Amgen Inc. | +18.69% | +3.71% |
